[Pulmonary arterial hypertension and BMP system abnormality]

Area of Science:

• Cardiovascular Genetics
• Molecular Biology
• Cell Biology

Context:

• Familial and idiopathic pulmonary arterial hypertension (PAH) are severe conditions characterized by pulmonary artery remodeling.
• Genetic analysis implicates germline mutations in the bone morphogenetic protein type II receptor (BMPRII) gene in PAH pathogenesis.
• BMPRII mutations disrupt normal cellular responses in pulmonary artery smooth muscle and endothelial cells.

Purpose:

• To summarize the current understanding of BMPRII mutations in PAH.
• To highlight the role of BMPRII in regulating smooth muscle cell proliferation and endothelial cell apoptosis.
• To identify gaps in knowledge regarding the molecular mechanisms of vascular remodeling in BMPRII-associated PAH.

Summary:

• Germline mutations in BMPRII are a key genetic factor in familial and idiopathic PAH.
• These mutations lead to aberrant signaling pathways, including unbalanced Smad signaling, affecting both smooth muscle cell proliferation and endothelial cell apoptosis.
• The combined effects of increased endothelial cell injury and reduced suppression of smooth muscle cell proliferation are critical in PAH development.

Impact:

• Understanding the role of BMPRII mutations provides insights into the cellular mechanisms driving PAH.
• This knowledge can inform the development of targeted therapies for PAH.
• Further research into the detailed molecular mechanisms is crucial for a comprehensive understanding and effective treatment of BMPRII-mutated PAH.